Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.47 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.47 |
| ▸ | ACACB | O00763 | 6/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13245465 | 0.83 | TAS1R3 (0.53) | TAS1R3TAS1R1ACACBNPSR1LMNA | |
| SCHEMBL13244952 | 0.82 | ACACB (0.37) | TAS1R3TAS1R1ACACBCA2 | |
| SCHEMBL3677101 | 0.78 | PTPN11 (0.49) | LMNAMEN1GAAKMT2ACA2 | |
| SCHEMBL13266965 | 0.75 | BCL2 (0.39) | TAS1R3TAS1R1CA2 | |
| SCHEMBL13245461 | 0.74 | KMT2A (0.54) | LMNAKMT2A | |
| SCHEMBL15382496 | 0.74 | ACACB (0.50) | TAS1R3TAS1R1ACACB | |
| SCHEMBL13984474 | 0.74 | PPARA (0.40) | ACACBNPSR1CA2CA1 | |
| SCHEMBL21889877 | 0.74 | TAS1R3 (0.59) | TAS1R3TAS1R1NPSR1MEN1KMT2A | |
| SCHEMBL13245353 | 0.74 | LMNA (0.51) | TAS1R3TAS1R1ACACBLMNA | |
| SCHEMBL25008944 | 0.74 | TAS1R3 (0.58) | TAS1R3TAS1R1ACACB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100190766-A1 | ANTIBACTERIAL AGENTS | ACHAOGEN, INC. (US) | 2010-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100190766-A1 | ANTIBACTERIAL AGENTS | MRPL21, SI, ABCB11 | TAS1R3 4086/4885TAS1R1 3410/4885ACACB 3224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.